Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07684287 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma

Name: A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma — clinical trial record (NCT07684287)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorCSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Started2026-08-01

View on ClinicalTrials.gov ↗

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

42 trials monitored

See 1 trial at risk

A Single-Arm, Non-Randomized, Open-Label Phase 2 Study of Nab-Sirolimus in Patients with Progressive or Symptomatic Epithelioid Hemangioendothelioma. Detailed Description: Avoid duplicating information that will be entered or uploaded elsewhere in the record.

Trial Details

NCT Number	NCT07684287
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	Epithelioid Hemangioendothelioma
Enrollment	40 participants
Start Date	2026-08-01
Primary Completion	2027-11-30 (estimated)
Study Completion	2027-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-06